ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

HLN Haleon

380.80
0.20 (0.05%)
Last Updated: 08:57:30
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Haleon LSE:HLN London Ordinary Share GB00BMX86B70 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.05% 380.80 380.70 380.90 381.60 379.10 380.00 332,529 08:57:30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices-holdng Companies,nec 11.3B 1.05B 0.1148 33.23 34.76B
Haleon is listed in the Offices-holdng Companies sector of the London Stock Exchange with ticker HLN. The last closing price for Haleon was 380.60p. Over the last year, Haleon shares have traded in a share price range of 310.45p to 400.50p.

Haleon currently has 9,133,887,197 shares in issue. The market capitalisation of Haleon is £34.76 billion. Haleon has a price to earnings ratio (PE ratio) of 33.23.

Haleon Share Discussion Threads

Showing 501 to 523 of 525 messages
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
DateSubjectAuthorDiscuss
29/11/2024
11:07
Out for now. Luck to holders.
philanderer
29/11/2024
11:07
Out for now. Luck to holders.
philanderer
25/11/2024
19:27
Haleon (formerly GlaxoSmithKline Consumer Healthcare) announced its 'HealthNxt' initiative to make consumer healthcare more accessible to more people in India by leveraging digital innovation, content, and technology.

Launched in partnership with WPP, the initiative focuses on raising awareness and advancing healthcare education across India.

philanderer
14/11/2024
12:25
Forward yield for 25 is only about 2% at 362p and a forecast 7.2p divi.
anhar
14/11/2024
10:20
#Anhar, a slow and steady growth share IMO, as the debt winds off dividends will increase, hopefully somewhere closer to the GSK 4% payout..

02.08.2023 - net debt at 30.06.2023 of GBP9,5BN with 3.4x net debt/adjusted EBITDA
29.02.2024 - net debt at 31.12.2023 of GBP8.5BN with 3.0x net debt/adjusted EBITDA
01.08.2024 - net debt at 30.06.2024 of GBP8.4BN with 2.9x net debt/adjusted EBITDA
31.10.2024 - target net debt/adjusted EBITDA of around 2.5x

laurence llewelyn binliner
14/11/2024
09:56
As an income investor I won't be adding at the current very low yield. Even a big rise in the divis of say 50% would still leave the yield too low for me to increase my holding with the share price around the present level. For most purchases, either top-ups or new holdings, I like to target a yield of at least 5% in current market conditions though I sometimes make exceptions to this for portfolio and diversification reasons.

I continue though to retain my holding from the GSK demerger as I think HLN has decent potential divi growth and my favoured approach is to to nothing.

anhar
13/11/2024
10:01
Yes, slippery slope continuing. Could really do with Pfizer dumping their final 15%
philanderer
12/11/2024
15:04
#Philanderer, IF it get close to that, I have been waiting to add here, as soon as we hit the debt leverage ratio target I am hoping dividends will take a big step up.. :o)
laurence llewelyn binliner
12/11/2024
14:21
Be testing 320p shortly at this rate.
philanderer
08/11/2024
14:13
Nice non-exec director buy this week

33,923 @ £3.6848p

philanderer
06/11/2024
09:27
No reasons, share prices mostly move randomly.
anhar
05/11/2024
18:41
Profit taking. Labour government. General uncertainty.
patientcapital
05/11/2024
14:22
Most UK shares are, despite being significantly undervalued versus other markets
dope007
05/11/2024
14:19
Why may i ask the share price is always going down, daily !
abdullla
05/11/2024
11:02
Berenberg: Haleon on road to growth


Haleon (HLN), the consumer health group spun out of GSK, is en route to a more ‘balanced growth algorithm’, says Berenberg.

Analyst Bethan Davies retained her ‘buy’ recommendation and increased the target price marginally from 454p to 456p on the Citywire Elite Companies A-rated owner of brands such as Sensodyne and Panadol, which softened 0.2% to 371.4p yesterday, but is and is up 17% since listing in 2022.

Davies said catalysts for the stock price were becoming ‘increasingly visible’ and she is expecting volume growth to accelerate in the fourth quarter to 3.6% from 2.8% in the third quarter.

Erectile dysfunction drug Eroxon has also been launched in the US and she expects this to contribute to organic sales growth next year.

On top of this, management is planning a capital markets day in the first half of next year, ‘which we expect will remind investors of the structural growth opportunities within Haleon’s core categories’.

‘We continue to see an additional optionality from a post-overhang re-rating as Pfizer continues to sell down its stake in Haleon,’ she said.


citywire.com

philanderer
31/10/2024
16:15
Yep, that’ll do , thanks anhar 👍
philanderer
31/10/2024
09:24
Trading statement here:
anhar
31/10/2024
08:11
Lots of companies doing well but billions is being yanked out of UK stocks thanks to these incompetents
dope007
31/10/2024
07:58
Solid trading statement.
patientcapital
17/10/2024
10:09
Berenberg raises Haleon price target to 454 (447) pence - 'buy'
philanderer
16/10/2024
23:32
Haleon Investing £130m In Oral Health Innovation Centre
philanderer
08/10/2024
10:02
UBS raises Haleon price target to 445 (410) pence - 'buy'

Deutsche Bank raises Haleon price target to 375 (340) pence - 'hold'

Barclays cuts Haleon price target to 406 (407) pence - 'overweight'

philanderer
07/10/2024
16:29
Total volume traded 23 million shares. Quite a few unloading.
philanderer
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older

Your Recent History

Delayed Upgrade Clock